PATENT CLAIM ANALYSIS

Application Number: 16014231
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "259300"]

Abstract:
Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Claim (Index 33):
The method of  claim 32 , wherein the disease is selected from the group consisting of Crohn's disease, ulcerative colitis, Irritable Bowel Disorder (IBD), asthma, graft versus host disease, allograft rejection, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, psoriasis, systemic onset juvenile idiopathic arthritis, multiple sclerosis, neuropathic pain, gout, and gouty arthritis.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.21739
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15905524', '15305390', '15247429', '15822493', '15305372']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8431328653661165
- 35 USC 102 Novelty (BERT): 0.5423703469891075
- Combined Prediction Score: 0.8130566135284156
- Mean Citation Score: 404.523194
- Max Citation Score: 418.23807
- Similarity Product: 266.845341511429

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test